Clinical efficacy and prognosis of different schemes for acute myeloid leukemia in elderly patients

Abstract

Objective To investigate the clinical efficacy and prognosis of elderly patients with acute myeloid leukemia treated with different regimens. Methods A total of 76 elderly patients with acute myeloid leukemia were divided into control group and observation group by random number table, with 38 cases in each group. The patients in the control group were given standard dose chemotherapy, and the patients in the observation group were given dose-lowering chemotherapy. The total effective rate, median survival time and incidence of adverse reactions in the two groups were compared. Results The total effective rate of the observation group and control group was 63.16% (24/38) and 60.53% (23/38), respectively, and the complete response rate was 31.57% (12/38) and 36.84% (14/38), respectively, there was no significant difference between the two groups in the two indicators (χ2=0.234, 0.056, P>0.05). The median survival time of the observation group and the control group were (14.38±1.47) months and (13.84±1.63) months, there was no significant difference between the two groups (P>0.05). However, the incidences of hemorrhage and organ dysfunction in the observation group were significantly lower than those in the control group (χ2=7.664, 4.828, P<0.05). Conclusions The clinical efficacy and complete remission rate of elderly patients with acute myeloid leukemia treated with standard dose chemotherapy and dose-reduction chemotherapy are similar, but the dose-reduction chemotherapy can effectively reduce the incidence of adverse reactions, and has higher safety and clinical promotion value. Key words: Elderly acute myeloid leukemia; Standard dose chemotherapy; Dose-lowering chemotherapy